# Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

> **NCT01339910** · PHASE3 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 272 (actual)

## Conditions studied

- Leukemia, Myelocytic, Acute

## Interventions

- **DRUG:** Fludarabine and Busulfan
- **DRUG:** Fludarabine and Melphalan
- **DRUG:** Busulfan and Fludarabine
- **DRUG:** Busulfan and Cyclophosphamide
- **DRUG:** Cyclophosphamide and Total Body Irradiation

## Key facts

- **NCT ID:** NCT01339910
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2017-01-16
- **Final completion:** 2017-10-16
- **Target enrollment:** 272 (ACTUAL)
- **Why stopped:** Accrual terminated as recommended by the data and safety monitoring board.
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339910, "Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01339910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*